Cardiac Death, Heart Attack, Stroke & Heart Failure
In February of 2019, the U.S. Food and Drug Administration (FDA) issued Black Box Warning for Takeda’s gout medication, Uloric. The boxed statement warns of an increased risk of cardiac death associated with the medication and recommends that use of Uloric be restricted to patients who cannot take other drugs for treatment of their gout. Uloric’s manufacturer, Takeda may be facing a number of lawsuits due to cardiac death and other serious cardiovascular side effects caused by the medication.
|Classification||xanthine oxidase inhibitor anti-gout|
|Dosage form(s)||40mg tablet|
|Normal dosage||40 to 80mg daily|
Uloric Cardiac Death
Gout is an inflammatory condition that occurs when blood levels of uric acid are high. It affects more than 8 million people in the U.S. and causes swelling and pain of the joints, resulting in near disability for some people. Uloric (febuxostat) is a medication which is used to treat gout and which works to reduce uric acid levels in the bloodstream by inhibiting the xanthine oxidase (XO) enzyme which is needed to make uric acid.
Uloric has been linked to an increased risk of cardiac death, such as fatal heart attack and stroke, in patients who take the medication. The increased risk was shown after results of a cardiac side effects study, known as the CARES study was performed.
The CARES study involved over 6,000 patients who were on either Uloric or another gout medication, allopurinol and who were followed for at least 32 months, some as long as 6.5 years. Patients who use Uloric were shown to be 34% more likely to experience cardiac death than those who were taking allopurinol, another gout treatment. Patients who have prior cardiac disease history may be at added risk.
Results showed that the increased incidence of cardiac death occurred in all subgroups including gender, age, kidney status and other medication use. In addition, to increased cardiac death risk, patients taking Uloric were shown to be at 22% greater risk for death due to other causes and were also at increased risk for non-fatal cardiac events.
Based on the increased link to cardiovascular death, consumer watchdog, Public Citizen, has stated that if cardiovascular results had been known at the time of Uloric’s original new drug application, the medication would never have been approved for use in the U.S. in 2009. Public Citizen has called for the withdrawal of Uloric from the market. Instead, the FDA has opted to require a black box warning.
Uloric Black Box Warning
On February 21, 2019, the FDA issued a safety communication announcing the conclusion of an in-depth review of safety results. The Agency announced that a black box warning would be mandatory on all prescribing information for Uloric and required the issuance of a patient medication guide.
A black box or boxed statement warning is the most severe safety alert that is issued by the FDA and is required to be printed at the top of drug labeling, enclosed in a box with a thick, black border. Uloric’[s black box warning states that the medication has been linked to an increased risk of cardiovascular death and all-cause death and that the medication should be reserved for use in patients who cannot take or have not responded to allopurinol for treatment of their gout.
The new medication guide for Uloric includes information about the increased cardiovascular death risk and recommends that patients inform their health care practitioner about history of heart problems or stroke.
It also advises patients to seek emergency medical assistance for symptoms that may indicate heart attack or stroke including:
- Chest pain
- Shortness of breath
- Irregular or rapid heartbeat
- Weakness or numbness on one side of body
- Speech difficulties
- Sudden headache
Uloric Lawsuit Claims
Takeda had marketed Uloric as a better treatment because it was easier to prescribe than another medication (allopurinol) which required more titration and lab testing, and tended to leave patients without adequate gout coverage. Unfortunately, Takeda may not have disclosed all of the risks of Uloric and many patients may have been placed at risk of serious cardiovascular side effects or death due to the medication.
Users of Uloric who suffered heart attack, heart failure, stroke, or cardiac death while taking or shortly after discontinuing Uloric treatment are filing lawsuits against Takeda pharmaceuticals. Lawsuits may be asking for compensation for medical costs, lost wages, pain and suffering or for wrongful death when a loved one has died.
Fill out the form or call for a free case evaluation.
- Make Uloric Second-Line for Gout, FDA Advisors Say, MedPage Today (01/2019)
- FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat), U.S. Food and Drug Administration (02/2019)
- Uloric Prescribing Information, RxList (03/2019)